Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus plantarum PL-02
- Development stage
- Unknown
- Lead developer
- Bioflag Biotech
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus plantarum PL-02 is a specific probiotic strain of human origin, originally isolated from the intestinal tract of an Olympic weightlifting gold medalist. It is primarily developed and studied for its ergogenic effects, including the enhancement of muscle mass, grip strength, and endurance performance, as well as its anti-fatigue properties. The strain is thought to function via the gut-muscle axis by reducing exercise-induced oxidative stress and inflammatory markers like lactate and ammonia while increasing glycogen storage. Beyond sports nutrition, PL-02 has been investigated in clinical trials for Alzheimer's disease as part of a multi-strain probiotic regimen aimed at modulating the gut-brain axis to improve cognitive function and increase levels of brain-derived neurotrophic factor (BDNF).
- Other names
- Lactiplantibacillus plantarum PL-02L. plantarum PL-02human-origin Lactobacillus plantarum PL-02
02
Targets
Misfolded SOD1IL1B (Interleukin-1 beta)BDNF (Brain-derived neurotrophic factor)
Beyond the preview
Go deeper on lactobacillus plantarum PL-02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus plantarum PL-02.